-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum Announces Investor Event and Conference Participation for April
07 Apr 2021Notice of Annual General Meeting in Immunicum am (publ)
31 Mar 2021Immunicum AB (publ) Announces Updated Executive Management Team After Business Combination
16 Mar 2021
Latest Corporate presentation
Immunicum Company PresentationNews
-
Corporate Presentation April
7 Apr 2021 -
Corporate Presentation – February 2021
22 Feb 2021 -
Virtual Investor Event Materials
8 Dec 2020 -
Transaction Webcast Presentation
19 Nov 2020 -
Transaction Webcast Details
18 Nov 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to treat hematologic and solid tumors.
Learn more
